ATEA PHARMACEUTICALS INC (AVIR)
Health Care · Clinical-stage antiviral biopharmaceuticals · NASDAQ
A clinical-stage antiviral company advancing pan-genotypic HCV and HEV therapies toward FDA submissions, leveraging proprietary nucleoside/nucleotide chemistry for differentiated viral treatment regimens.
What ATEA PHARMACEUTICALS INC does
Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company developing novel, orally administered antivirals for serious viral diseases. The company's pipeline is focused on hepatitis C virus (HCV) treatment with bemnifosbuvir and ruzasvir, a pan-genotypic protease inhibitor-free regimen currently in Phase 3 clinical trials, and AT-587, a direct-acting antiviral (DAA) candidate for chronic hepatitis E virus (HEV) infection in immunocompromised patients.
Themes: ["Antiviral drug development"]
Fundamentals
- Price$4.91 as of 2026-07-09 close
- Market cap$393M as of 2026-07-10
- 1-year return+31.6% as of 2026-07-09 close
- Net margin+34.5% as of 2026-07-10
- ROE-57.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.27 as of 2026-07-10
Key risks (from latest filing)
["Phase 3 clinical trials for bemnifosbuvir/ruzasvir may not achieve successful efficacy or safety endpoints needed for FDA approval (C-BEYOND results expected mid-2026, C-FORWARD year-end 2026)"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.